Pharmacy & Drugstore Chains

The average Swiss Pharmacy & Drugstore Chains company is valued at 5.0 - 7.0× EBITDA on a statutory (tax-based) basis and 6.5 - 9.0× EBITDA in actual deal transactions. The spread between statutory and deal multiples represents a key arbitrage opportunity for informed buyers. The current market trend is consolidating, with an arbitrage gap rated as high. Actual valuations depend heavily on recurring revenue share, customer diversification, management depth, and equipment modernity.

Key valuation drivers include: Essential healthcare infrastructure with recession-resistant demand — pharmacies are a daily necessity for millions of Swiss residents; Swissmedic licensing creates a strong regulatory moat limiting new entrants; each pharmacy requires a licensed pharmacist as responsible person. Factors that can compress valuations include: BAG-regulated drug pricing and mandatory reference pricing compress prescription dispensing margins to thin levels, limiting profitability on ~60% of revenue; High fixed cost base — pharmacies require qualified pharmacists (CHF 120,000-150,000 salary), pharmacy assistants, and compliance with strict facility standards. Deal multiples typically range from 6.5 - 9.0× EBITDA, but actual prices vary significantly based on customer concentration, management quality, revenue predictability, and geographic reach within Switzerland's 26 cantons.

Approximately ~2,350 companies operate in Switzerland's Pharmacy & Drugstore Chains sector. Approximately 1,800 licensed pharmacies and 550 drugstores (Drogerien) across Switzerland The sector employs ~25,000 people and represents a market of CHF 7-8B. Company counts have been evolving due to consolidation trends and succession-driven market exits across Swiss SME sectors.

The Swiss pharmacy retail sector faces a significant succession wave driven by two converging forces: the aging demographic of independent pharmacy owners and the relentless consolidation pressure from chain operators. Approximately 40% of independent pharmacy owners in Switzerland are aged 55 or older, and many face the reality that their businesses are worth more to a chain acquirer like Galenica than as standalone operations. The Swissmedic pharmacy license and cantonal operating permits represent valuable intangible assets that create a floor valuation, but the true succession challenge li...

The 6 key trends shaping Swiss Pharmacy & Drugstore Chains are: (1) Consolidation and Chain Expansion; (2) Online Pharmacy and Digital Disruption; (3) Expanded Pharmaceutical Care Services; (4) Physician Self-Dispensation Debate; (5) OTC and Self-Medication Growth; (6) Sustainability and Green Pharmacy. The Swiss pharmacy landscape is consolidating rapidly, with the Galenica Group at the center of this transformation. Through its Amavita and Sun Store retail brands, the Coop Vitality joint venture, a... These trends directly impact company valuations and M&A activity in the sector.

The principal acquisition risks are: (1) Online pharmacy disruption from Zur Rose/DocMorris and international platforms eroding traditional pharmacy footfall and convenience advantage; (2) Continuing margin pressure from BAG triennial drug price reviews, reference pricing expansion, and health insurance cost containment measures; (3) Growing competition from drugstore chains (Müller, dm potential Swiss entry) and retail health concepts in supermarkets encroaching on OTC segment. Buyers should conduct thorough due diligence on customer concentration, regulatory compliance, and key-person dependencies. Deal multiples of 6.5 - 9.0× EBITDA may be discounted for firms with elevated risk profiles.

The typical cost breakdown for a Swiss Pharmacy & Drugstore Chains firm is: Purchased Goods (prescription medicines, OTC products): 62%, Personnel Costs (pharmacists, assistants, staff): 18%, Rent & Occupancy Costs: 7%, Logistics & Inventory Management: 3%, Regulatory Compliance & Insurance: 2%, Other Operating Costs (IT, marketing, depreciation): 3%, Profit Margin (EBITDA): 5%. Based on Swiss pharmacy retail industry averages (pharmasuisse, Galenica Annual Report). Prescription dispensing margins are compressed by BAG pricing regulation, while OTC and health/beauty segments offer higher gross margins. Individual pharmacies vary significantly based on location (urban vs. rural), chain affiliation, and OTC product mix weighting. These benchmarks are important for buyers assessing operational efficiency and margin improvement potential post-acquisition.

Switzerland's main Pharmacy & Drugstore Chains clusters are: (1) Greater Bern (BE); (2) Zurich Metropolitan Area (ZH); (3) Eastern Switzerland / Thurgau (TG, SG); (4) Romandie - Geneva / Lausanne (GE, VD); (5) Aargau / Central Switzerland (AG, LU, ZG). Headquarters of the Galenica Group, Switzerland's dominant pharmacy player. Home to Galexis central wholesale distribution (Niederbipp), Alloga pre-wh... Regional concentration affects valuations, as companies in established clusters benefit from supplier ecosystems, specialized talent pools, and industry networks.